These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 36999708)

  • 1. Pre-clinical Efficacy and Safety Pharmacology of PEGylated Recombinant Human Endostatin.
    Guo L; Hua L; Hu B; Wang J
    Curr Mol Med; 2024; 24(3):389-396. PubMed ID: 36999708
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quality, bioactivity study, and preclinical acute toxicity, safety pharmacology evaluation of PEGylated recombinant human endostatin (M
    Guo L; Geng X; Liu L; Miao Y; Lin Z; Yu M; Fu Y; Liu L; Li B; Luo Y
    J Biochem Mol Toxicol; 2019 Mar; 33(3):e22257. PubMed ID: 30536793
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A pre-clinical safety study of PEGylated recombinant human endostatin (M
    Geng X; Guo L; Liu L; Wang C; Peng Q; Qi W; Sun L; Liu X; Miao Y; Lin Z; Fu Y; Luo Y; Li B
    Regul Toxicol Pharmacol; 2018 Jun; 95():190-197. PubMed ID: 29580973
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparisons of biophysical properties and bioactivities of mono-PEGylated endostatin and an endostatin analog.
    Wang S; Fu Y; Luo Y
    Chin J Cancer; 2016 Jan; 35():14. PubMed ID: 26792627
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pre-clinical toxicokinetics and safety study of M2ES, a PEGylated recombinant human endostatin, in rhesus monkeys.
    Guo L; Geng X; Chen Y; Qi F; Liu L; Miao Y; Lin Z; Yu M; Li Z; Fu Y; Li B; Luo Y
    Regul Toxicol Pharmacol; 2014 Aug; 69(3):512-23. PubMed ID: 24878240
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of PEGylated recombinant human endostatin in rhesus monkeys.
    Guo L; Li Z; Xu B; Yu M; Fu Y; Liu L; Wang J; Luo Y
    Life Sci; 2019 Dec; 238():116967. PubMed ID: 31626794
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of PEGylated recombinant human endostatin (M2ES) in rats.
    Li ZG; Jia L; Guo LF; Yu M; Sun X; Nie W; Fu Y; Rao CM; Wang JZ; Luo YZ
    Acta Pharmacol Sin; 2015 Jul; 36(7):847-54. PubMed ID: 26027657
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biophysical and biological characterization of PEGylated recombinant human endostatin.
    Guo L; Xu B; Zhou D; Chang G; Fu Y; Liu L; Luo Y
    Clin Exp Pharmacol Physiol; 2019 Oct; 46(10):920-927. PubMed ID: 31278773
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetically engineered endostatin-lidamycin fusion proteins effectively inhibit tumor growth and metastasis.
    Jiang WG; Lu XA; Shang BY; Fu Y; Zhang SH; Zhou D; Li L; Li Y; Luo Y; Zhen YS
    BMC Cancer; 2013 Oct; 13():479. PubMed ID: 24128285
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I trial of M
    Chen Y; DU Y; Li P; Wu F; Fu Y; Li Z; Luo Y
    Mol Clin Oncol; 2014 Jul; 2(4):586-590. PubMed ID: 24940500
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endostatin inhibits tumour lymphangiogenesis and lymphatic metastasis via cell surface nucleolin on lymphangiogenic endothelial cells.
    Zhuo W; Luo C; Wang X; Song X; Fu Y; Luo Y
    J Pathol; 2010 Nov; 222(3):249-60. PubMed ID: 20814900
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antitumor efficacy of a recombinant adenovirus encoding endostatin combined with an E1B55KD-deficient adenovirus in gastric cancer cells.
    Li LX; Zhang YL; Zhou L; Ke ML; Chen JM; Fu X; Ye CL; Wu JX; Liu RY; Huang W
    J Transl Med; 2013 Oct; 11():257. PubMed ID: 24124726
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic efficacy of recombinant human endostatin combined with chemotherapeutics in mice-transplanted tumors.
    Zhu LP; Xing J; Wang QX; Kou L; Li C; Hu B; Wu ZW; Wang JJ; Xu GX
    Eur J Pharmacol; 2009 Sep; 617(1-3):23-7. PubMed ID: 19615993
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endostar-loaded PEG-PLGA nanoparticles: in vitro and in vivo evaluation.
    Hu S; Zhang Y
    Int J Nanomedicine; 2010 Nov; 5():1039-48. PubMed ID: 21170352
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-tumor effect of a novel soluble recombinant human endostatin: administered as a single agent or in combination with chemotherapy agents in mouse tumor models.
    Ren Z; Wang Y; Jiang W; Dai W; Jiang Y
    PLoS One; 2014; 9(9):e107823. PubMed ID: 25229620
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of recombinant human endostatin and its synergy with cisplatin on circulating endothelial cells and tumor vascular normalization in A549 xenograft murine model.
    Li N; Zheng D; Wei X; Jin Z; Zhang C; Li K
    J Cancer Res Clin Oncol; 2012 Jul; 138(7):1131-44. PubMed ID: 22402599
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preparation and stability of N-terminal mono-PEGylated recombinant human endostatin.
    Nie Y; Zhang X; Wang X; Chen J
    Bioconjug Chem; 2006; 17(4):995-9. PubMed ID: 16848407
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombinant human endostatin endostar inhibits tumor growth and metastasis in a mouse xenograft model of colon cancer.
    Jia Y; Liu M; Huang W; Wang Z; He Y; Wu J; Ren S; Ju Y; Geng R; Li Z
    Pathol Oncol Res; 2012 Apr; 18(2):315-23. PubMed ID: 21938482
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Inhibition of tumor growth and metastasis via local administration of recombinant human endostatin adenovirus].
    Wu Y; Yang L; Zhao X; Su JM; Hu B; Liu JY; Niu T; Luo Y; Li Q; Wei YQ
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2004 Dec; 21(6):557-61. PubMed ID: 15583981
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Down-regulation of vascular endothelial growth factor and up-regulation of pigment epithelium derived factor make low molecular weight heparin-endostatin and polyethylene glycol-endostatin potential candidates for anti-angiogenesis drug.
    Tan H; Mu G; Zhu W; Liu J; Wang F
    Biol Pharm Bull; 2011; 34(4):545-50. PubMed ID: 21467643
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.